ISRG vs LLY

Intuitive Surgical (ISRG) continues to demonstrate strong operational performance, evidenced by its Q4 2025 revenue growth of 18.8% YoY and robust EPS beat. It maintains its undisputed leadership in robotic-assisted surgery, supported by a growing installed base of 11,423 da Vinci systems and impressive Ion system adoption. The company's formidable moat, built on IP, high switching costs, and exte...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...